Tokyo Tape
Sign in
← Falco Holdings

Quarterly report · Q1

4671.TEDINET S100RP4T
Period2023-04-01 → 2023-06-30
Filed2023-08-14
StandardJapan GAAP
ConsolidatedYes
Data checks12 of 12 passed
Key figures · 34
MetricValuePeriodScopeSource row
Revenue¥10.6bn2023-04-01 → 2023-06-30Cons.Net sales
Revenue¥46.9bn2022-04-01 → 2023-03-31Cons.Net sales (5-year summary)
Revenue¥11.6bn2022-04-01 → 2022-06-30Cons.Net sales
Operating income¥249m2023-04-01 → 2023-06-30Cons.Operating income
Operating income¥681m2022-04-01 → 2022-06-30Cons.Operating income
Ordinary income¥303m2023-04-01 → 2023-06-30Cons.Ordinary income
Ordinary income¥3.3bn2022-04-01 → 2023-03-31Cons.Ordinary income loss (5-year summary)
Ordinary income¥769m2022-04-01 → 2022-06-30Cons.Ordinary income
Profit before tax¥292m2023-04-01 → 2023-06-30Cons.Income before income taxes
Profit before tax¥748m2022-04-01 → 2022-06-30Cons.Income before income taxes
Net income (owners)¥124m2023-04-01 → 2023-06-30Cons.Profit loss attributable to owners of parent
Net income (owners)¥2.3bn2022-04-01 → 2023-03-31Cons.Profit loss attributable to owners of parent (5-year summary)
Net income (owners)¥442m2022-04-01 → 2022-06-30Cons.Profit loss attributable to owners of parent
Net income¥124m2023-04-01 → 2023-06-30Cons.Profit loss
Net income¥442m2022-04-01 → 2022-06-30Cons.Profit loss
Total assets¥37.1bnat 2023-06-30Cons.Assets
Total assets¥38.9bnat 2023-03-31Cons.Assets
Total assets¥38.2bnat 2022-06-30Cons.Total assets (5-year summary)
Total liabilities¥11.2bnat 2023-06-30Cons.Liabilities
Total liabilities¥12.3bnat 2023-03-31Cons.Liabilities
Net assets / equity¥26.0bnat 2023-06-30Cons.Net assets
Net assets / equity¥26.6bnat 2023-03-31Cons.Net assets
Net assets / equity¥23.6bnat 2022-06-30Cons.Net assets (5-year summary)
Cash and deposits¥9.6bnat 2023-06-30Cons.Cash and deposits
Cash and deposits¥12.6bnat 2023-03-31Cons.Cash and deposits
EPS (basic)¥11.072023-04-01 → 2023-06-30Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥215.292022-04-01 → 2023-03-31Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥42.322022-04-01 → 2022-06-30Cons.Basic earnings loss per share (5-year summary)
EPS (diluted)¥11.052023-04-01 → 2023-06-30Cons.Diluted earnings per share (5-year summary)
EPS (diluted)¥214.032022-04-01 → 2023-03-31Cons.Diluted earnings per share (5-year summary)
EPS (diluted)¥42.252022-04-01 → 2022-06-30Cons.Diluted earnings per share (5-year summary)
Equity ratio69.7%at 2023-06-30Cons.Equity to asset ratio (5-year summary)
Equity ratio68.2%at 2023-03-31Cons.Equity to asset ratio (5-year summary)
Equity ratio61.5%at 2022-06-30Cons.Equity to asset ratio (5-year summary)

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 36
SegmentItemPeriodValue
Reconciling Itemsreconcilingrevenue2023-04-01 → 2023-06-30¥0
Reconciling Itemsreconcilingrevenue intersegment2023-04-01 → 2023-06-30¥0
Reconciling Itemsreconcilingsegment profit2023-04-01 → 2023-06-30−¥145m
jpcrp040300-q1r_E04982-000Clinical Testing Businessreportable segmentrevenue2023-04-01 → 2023-06-30¥6.6bn
jpcrp040300-q1r_E04982-000Clinical Testing Businessreportable segmentrevenue external2023-04-01 → 2023-06-30¥6.6bn
jpcrp040300-q1r_E04982-000Clinical Testing Businessreportable segmentrevenue intersegment2023-04-01 → 2023-06-30¥0
jpcrp040300-q1r_E04982-000Clinical Testing Businessreportable segmentsegment profit2023-04-01 → 2023-06-30¥348m
jpcrp040300-q1r_E04982-000Dispensing Pharmacy Businessreportable segmentrevenue2023-04-01 → 2023-06-30¥3.9bn
jpcrp040300-q1r_E04982-000Dispensing Pharmacy Businessreportable segmentrevenue external2023-04-01 → 2023-06-30¥3.9bn
jpcrp040300-q1r_E04982-000Dispensing Pharmacy Businessreportable segmentrevenue intersegment2023-04-01 → 2023-06-30¥0
jpcrp040300-q1r_E04982-000Dispensing Pharmacy Businessreportable segmentsegment profit2023-04-01 → 2023-06-30¥55m
jpcrp040300-q1r_E04982-000ICT Businessreportable segmentrevenue2023-04-01 → 2023-06-30¥190m
jpcrp040300-q1r_E04982-000ICT Businessreportable segmentrevenue external2023-04-01 → 2023-06-30¥190m
jpcrp040300-q1r_E04982-000ICT Businessreportable segmentsegment profit2023-04-01 → 2023-06-30−¥8m
—segment totalrevenue2023-04-01 → 2023-06-30¥10.6bn
—segment totalrevenue external2023-04-01 → 2023-06-30¥10.6bn
—segment totalrevenue intersegment2023-04-01 → 2023-06-30¥0
—segment totalsegment profit2023-04-01 → 2023-06-30¥395m
Reconciling Itemsreconcilingrevenue2022-04-01 → 2022-06-30−¥4m
Reconciling Itemsreconcilingrevenue intersegment2022-04-01 → 2022-06-30−¥4m
Reconciling Itemsreconcilingsegment profit2022-04-01 → 2022-06-30−¥108m
jpcrp040300-q1r_E04982-000Clinical Testing Businessreportable segmentrevenue2022-04-01 → 2022-06-30¥7.6bn
jpcrp040300-q1r_E04982-000Clinical Testing Businessreportable segmentrevenue external2022-04-01 → 2022-06-30¥7.6bn
jpcrp040300-q1r_E04982-000Clinical Testing Businessreportable segmentrevenue intersegment2022-04-01 → 2022-06-30¥3m
jpcrp040300-q1r_E04982-000Clinical Testing Businessreportable segmentsegment profit2022-04-01 → 2022-06-30¥855m
jpcrp040300-q1r_E04982-000Dispensing Pharmacy Businessreportable segmentrevenue2022-04-01 → 2022-06-30¥3.9bn
jpcrp040300-q1r_E04982-000Dispensing Pharmacy Businessreportable segmentrevenue external2022-04-01 → 2022-06-30¥3.9bn
jpcrp040300-q1r_E04982-000Dispensing Pharmacy Businessreportable segmentrevenue intersegment2022-04-01 → 2022-06-30¥0
jpcrp040300-q1r_E04982-000Dispensing Pharmacy Businessreportable segmentsegment profit2022-04-01 → 2022-06-30¥6m
jpcrp040300-q1r_E04982-000ICT Businessreportable segmentrevenue2022-04-01 → 2022-06-30¥102m
jpcrp040300-q1r_E04982-000ICT Businessreportable segmentrevenue external2022-04-01 → 2022-06-30¥102m
jpcrp040300-q1r_E04982-000ICT Businessreportable segmentsegment profit2022-04-01 → 2022-06-30−¥73m
—segment totalrevenue2022-04-01 → 2022-06-30¥11.6bn
—segment totalrevenue external2022-04-01 → 2022-06-30¥11.6bn
—segment totalrevenue intersegment2022-04-01 → 2022-06-30¥4m
—segment totalsegment profit2022-04-01 → 2022-06-30¥789m

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 358
ItemContextValueUnit
Revenues from external customersCurrentYTDDuration_ReconcilingItemsMember－JPY
Revenues from external customersCurrentYTDDuration10638000000JPY
Transactions with other segmentsCurrentYTDDuration_jpcrp040300-q1r_E04982-000ClinicalTestingBusinessReportableSegmentsMember0JPY
Transactions with other segmentsCurrentYTDDuration_jpcrp040300-q1r_E04982-000DispensingPharmacyBusinessReportableSegmentsMember0JPY
Transactions with other segmentsCurrentYTDDuration_jpcrp040300-q1r_E04982-000ICTBusinessReportableSegmentsMember－JPY
Transactions with other segmentsCurrentYTDDuration_ReportableSegmentsMember0JPY
Transactions with other segmentsCurrentYTDDuration_ReconcilingItemsMember-0JPY
Transactions with other segmentsCurrentYTDDuration－JPY
Net salesCurrentYTDDuration_jpcrp040300-q1r_E04982-000ClinicalTestingBusinessReportableSegmentsMember6560000000JPY
Net salesCurrentYTDDuration_jpcrp040300-q1r_E04982-000DispensingPharmacyBusinessReportableSegmentsMember3887000000JPY
Net salesCurrentYTDDuration_jpcrp040300-q1r_E04982-000ICTBusinessReportableSegmentsMember190000000JPY
Net salesCurrentYTDDuration_ReportableSegmentsMember10638000000JPY
Net salesCurrentYTDDuration_ReconcilingItemsMember-0JPY
Net salesCurrentYTDDuration10638000000JPY
Operating incomeCurrentYTDDuration_jpcrp040300-q1r_E04982-000ClinicalTestingBusinessReportableSegmentsMember348000000JPY
Operating incomeCurrentYTDDuration_jpcrp040300-q1r_E04982-000DispensingPharmacyBusinessReportableSegmentsMember55000000JPY
Operating incomeCurrentYTDDuration_jpcrp040300-q1r_E04982-000ICTBusinessReportableSegmentsMember-8000000JPY
Operating incomeCurrentYTDDuration_ReportableSegmentsMember395000000JPY
Operating incomeCurrentYTDDuration_ReconcilingItemsMember-145000000JPY
Operating incomeCurrentYTDDuration249000000JPY
Document title cover pageFilingDateInstant
Original text (Japanese)四半期報告書
Clause of stipulation cover pageFilingDateInstant
Original text (Japanese)金融商品取引法第24条の４の７第１項
Place of filing cover pageFilingDateInstant
Original text (Japanese)近畿財務局長
Filing date cover pageFilingDateInstant2023-08-14
Quarterly accounting period cover pageFilingDateInstant
Original text (Japanese)第37期第１四半期（自　令和５年４月１日　至　令和５年６月30日）
Company name cover pageFilingDateInstant
Original text (Japanese)株式会社ファルコホールディングス
Company name in english cover pageFilingDateInstantFALCO HOLDINGS Co., Ltd.
Title and name of representative cover pageFilingDateInstant
Original text (Japanese)代表取締役社長執行役員　　安田　忠史
Address of registered headquarter cover pageFilingDateInstant
Original text (Japanese)京都市左京区聖護院蓮華蔵町44番地３（同所は登記上の本店所在地で実際の管理業務は「最寄りの連絡場所」で行っております。）
Telephone number address of registered headquarter cover pageFilingDateInstant－
Name of contact person address of registered headquarter cover pageFilingDateInstant－
Nearest place of contact cover pageFilingDateInstant
Original text (Japanese)大阪市中央区内平野町１丁目３番７号
Telephone number nearest place of contact cover pageFilingDateInstant０６－７６３２－６１５０
Name of contact person nearest place of contact cover pageFilingDateInstant
Original text (Japanese)執行役員管理室長　　大馬　久幸
Place for public inspection cover page (text)FilingDateInstantText · Plus
Edinet codeFilingDateInstantE04982
Fund codeFilingDateInstant－
Security codeFilingDateInstant46710
Filer name in japaneseFilingDateInstant
Original text (Japanese)株式会社ファルコホールディングス
Filer name in englishFilingDateInstantFALCO HOLDINGS Co., Ltd.
Fund name in japaneseFilingDateInstant－
Fund name in englishFilingDateInstant－
Cabinet office ordinanceFilingDateInstant
Original text (Japanese)企業内容等の開示に関する内閣府令
Document typeFilingDateInstant
Original text (Japanese)第四号の三様式
Accounting standardsFilingDateInstantJapan GAAP
Whether consolidated financial statements are preparedFilingDateInstanttrue
Industry code when consolidated financial statements are prepared in accordance with industry specific regulationsFilingDateInstantCTE
Industry code when financial statements are prepared in accordance with industry specific regulationsFilingDateInstant－
Current fiscal year start dateFilingDateInstant2023-04-01
Current period end dateFilingDateInstant2023-06-30

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 12 of 12 passed
balance sheet identityconsolidated 2023-03-31pass rounding
balance sheet identityconsolidated 2023-06-30pass
dei present pass
period resolution pass
statement vs summary · net assetsconsolidated 2023-03-31pass
statement vs summary · net assetsconsolidated 2023-06-30pass
statement vs summary · net income attributable to parentconsolidated 2022-04-01/2022-06-30pass
statement vs summary · net income attributable to parentconsolidated 2023-04-01/2023-06-30pass
statement vs summary · revenueconsolidated 2022-04-01/2022-06-30pass
statement vs summary · revenueconsolidated 2023-04-01/2023-06-30pass
statement vs summary · total assetsconsolidated 2023-03-31pass
statement vs summary · total assetsconsolidated 2023-06-30pass